How tirzepatide is used for weight loss in the UK

What is tirzepatide actually doing inside the body?

Most people who ask this question have heard vague references to "gut hormones" and assume it simply suppresses appetite. That part is true, but the picture is more specific. Tirzepatide mimics two hormones (GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1)) that are naturally released after eating. By activating both receptors at once, it slows how quickly food leaves the stomach, signals to the brain that you have eaten, and reduces the drive to keep eating past the point of fullness. No other weight-loss medicine licensed in the UK works this way; Mounjaro's dual mechanism sets it apart from single-pathway GLP-1 treatments.

One misconception that turns up repeatedly: people assume tirzepatide is essentially the same as the older GLP-1 injections with a different name. It is related in that both drug classes involve gut-hormone pathways, but adding the GIP pathway appears to produce meaningfully greater average weight reduction, as the head-to-head SURMOUNT-5 trial published in the New England Journal of Medicine in 2025 confirmed. The evidence on how much weight people actually lose is worth reading in full if you want the trial figures unpacked properly.

Because gastric emptying slows, the most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and, sometimes, burping. These tend to be most noticeable in the first few weeks or after a dose increase, and they settle for most people. They are also, incidentally, part of the reason the medicine starts at a low dose before stepping up.

Who does the UK licence actually cover?

The licence covers adults with a body mass index of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Those are the private licensed criteria; the NICE recommendation (TA1026) sets stricter thresholds for NHS access, requiring a BMI of 35 or higher and at least one comorbidity. Lower BMI thresholds apply for South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds under NICE's guidance, reflecting differences in how weight-related health risk presents across ethnic groups.

BMI alone does not determine suitability. A prescriber looks at your full health picture, including any conditions that might make the medicine unsuitable, a history of certain thyroid conditions or pancreatitis, for example, requires careful prescriber discussion. Pregnancy, breastfeeding and active plans to conceive are contraindications; tirzepatide is also not licensed for anyone under 18.

If you are taking an oral contraceptive pill, your prescriber should know: tirzepatide can reduce pill absorption during the first four weeks of treatment and for four weeks after each dose increase, and NHS guidance suggests adding a barrier method during those windows. The NHS England guidance on weight-management injections sets this out clearly, and it is the kind of detail a thorough clinical assessment covers.

What does the dosing schedule look like in practice?

Tirzepatide comes as a pre-filled KwikPen, one pen contains four weekly doses and is injected into the abdomen, thigh or upper arm, rotating sites each week. The pen is stored in the fridge. The tirzepatide dosing schedule runs from 2.5 mg up through 5, 7.5, 10 and 12.5 mg to the 15 mg maintenance dose, with the prescriber deciding the pace of increases based on how you are tolerating each level. That first pen at 2.5 mg exists to let your system adjust, not to produce noticeable weight loss, many people find the early weeks quieter than they expected, which is normal.

NICE's guidance notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing should be reviewed. That threshold matters because it frames tirzepatide as a tool that works alongside a calorie-reduced diet and increased physical activity, not instead of them. Prescribers at nume review every repeat order clinically, which means the reassessment is built in rather than left to chance.

For a realistic sense of costs involved in private treatment, the Mounjaro pricing page gives the context on what treatment typically costs in the UK private market and what a transparent price should include.

How does someone get a tirzepatide prescription in the UK?

Tirzepatide is a prescription-only medicine, which means the legal route in the UK is through a prescriber who has assessed your suitability, whether that is a GP, a specialist, or a GPhC-registered prescriber at a regulated online pharmacy. The NHS route is subject to the phased rollout criteria described above and, in many areas, waiting times. If you want to understand more about how tirzepatide is used for weight loss and whether you might be a suitable candidate, the detail on that page is a helpful starting point before you decide which route to pursue.

Whatever route you consider, verifying that the pharmacy is on the GPhC register is a basic and important check, the GPhC pharmacy register is public and searchable. The MHRA has issued repeated warnings about fake pens circulating online: counterfeit tirzepatide has been seized in the UK, and in October 2025 the first illicit UK manufacturing site producing fake tirzepatide pens was raided. Sellers offering these medicines without a prescription from a clinical assessment, or advertising prices far below the current market, are significant red flags. If you come across a suspect seller, it can be reported directly via the MHRA's Yellow Card scheme.

If you want to understand more about whether tirzepatide could be appropriate for you, starting a free consultation with our prescribers is the right first step. A real clinician reviews your answers the same day (not software) and that assessment is what makes the difference between treatment that is genuinely safe and treatment that merely looks convenient.